Trial Profile
An 8-week Multicenter, Randomized, Double-blind, Active Controlled, Parallel Group, Forced Titration Study to Evaluate the Efficacy and Safety of Aliskiren/Amlodipine/HCTZ Compared to Aliskiren/Amlodipine in US Minority Patients With Stage 2 Hypertension.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Jun 2011
Price :
$35
*
At a glance
- Drugs Aliskiren/amlodipine/hydrochlorothiazide (Primary) ; Aliskiren/amlodipine; Amlodipine
- Indications Hypertension
- Focus Registrational; Therapeutic Use
- Acronyms ASCENT
- 25 Aug 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
- 25 Aug 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 27 Jul 2009 New trial record